![]() ![]() ![]() We are also excited to welcome Paul Campanelli to the Endo leadership team. "We believe the acquisition of Par underscores the continued execution of Endo's value-driven M&A strategy and helps deliver on our goal of achieving double-digit revenue growth for the overall business over the long-term. This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A," said Rajiv De Silva, President and CEO of Endo. "Our generics business, Qualitest, continues to be an extremely attractive and effective growth driver for Endo. Endo expects to implement a permanent capital structure to finance the transaction prior to the close that would include a combination of cash, debt and an equity offering. Endo has secured fully committed financing from Deutsche Bank and Barclays to fund the cash consideration. The purchase price will consist of approximately 18 million shares ($1.55 billion of value based on the 10-day volume weighted average share price of Endo ending on May 15, 2015) of Endo equity and $6.50 billion cash consideration to Par shareholders. There are no further shareholder approvals required. The transaction has been unanimously approved by the Boards of Directors of Endo and Par, and is supported by the management teams of both companies. It is also expected to help drive long-term double-digit revenue growth for Endo. The combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry's fastest growing and among the top five as measured by U.S. today announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt. Par CEO Paul Campanelli to join Endo to lead generics business and join Executive Leadership TeamÄublin Ireland and Woodcliff Lake, NJ /PRNewswire/ - Endo International plc (NASDAQ: ENDP) (TSX: ENL) and Par Pharmaceutical Holdings, Inc.Projected total operational and tax synergies of $175 million while strategically maintaining R&D.Accretive to non-GAAP diluted earnings per share within first 12 months with double-digit accretion to non-GAAP diluted earnings per share expected in 2016.Positions Endo for long-term double-digit organic growth, strong cash flow and financial flexibility.Creates specialty pharmaceutical company with one of industry's fastest growing generics businesses and expanded product portfolio, pipeline, technology platform and manufacturing capabilities.Transaction valued at $8.05 billion is transformative for Endo, creating a powerful platform for future growth and further strategic M&A.With a sterile manufacturing facility located in Rochester, Michigan, Par Sterile Products possesses an unparalleled reputation for high-quality products and an impeccable record of regulatory compliance. Par Sterile Products develops, manufactures and markets a broad portfolio of branded and generic aseptic injectable products. Our focus is on therapeutically equivalent ANDA-based products, and others on a case-by-case basis. Par Pharmaceutical specializes in modified-released oral solid dosage forms as well as non-oral dosage forms, such as nasal sprays, inhalers, patches and other alternative drug delivery platforms. We offer high-quality, cost-effective products with the highest level of customer service. Par Pharmaceutical, a wholly owned Endo business, is a highly focused generic pharmaceutical company dedicated to delivering quality medicines to patients in need through excellence in innovation, development, manufacturing, and commercialization. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |